UBS analyst Danielle Antalffy lowered the firm’s price target on Treace Medical (TMCI) to $6.50 from $8.60 and keeps a Neutral rating on the shares. Treace Medical reported a modest sales beat and adjusted EBITDA progression, and 2025 guidance implies double digit growth in the second half of the year, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical Concepts Reports Q2 2025 Financial Results
- Treace Medical reports Q2 EPS (28c), consensus (29c)
- Treace Medical backs FY25 revenue view $224M-$230M, consensus $227.03M
- Treace Medical management to meet virtually with Lake Street
- Treace Medical publishes four-year interim results from ALIGN3D study